Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial (Blood, 2017)

(untitled) - Harrison, C; Mead, A; Panchal, A; Fox, S; Yap, C; Gbandi, E; Houlton, A; Alimam, S; Ewing, J; Wood, M; Chen, F; Coppell, J; et al.